EP0563697A3 - Cytarabine ocfosfate hard capsule - Google Patents

Cytarabine ocfosfate hard capsule Download PDF

Info

Publication number
EP0563697A3
EP0563697A3 EP19930104505 EP93104505A EP0563697A3 EP 0563697 A3 EP0563697 A3 EP 0563697A3 EP 19930104505 EP19930104505 EP 19930104505 EP 93104505 A EP93104505 A EP 93104505A EP 0563697 A3 EP0563697 A3 EP 0563697A3
Authority
EP
European Patent Office
Prior art keywords
hard capsule
cytarabine ocfosfate
ocfosfate hard
cytarabine
capsule
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
EP19930104505
Other versions
EP0563697A2 (en
EP0563697B1 (en
Inventor
Minoru Aoki
Hiroshi Ohtaki
Minoru Nakada
Nobuharu Fukui
Takashi Terada
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Nippon Kayaku Co Ltd
Original Assignee
Nippon Kayaku Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Nippon Kayaku Co Ltd filed Critical Nippon Kayaku Co Ltd
Publication of EP0563697A2 publication Critical patent/EP0563697A2/en
Publication of EP0563697A3 publication Critical patent/EP0563697A3/en
Application granted granted Critical
Publication of EP0563697B1 publication Critical patent/EP0563697B1/en
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1635—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1652—Polysaccharides, e.g. alginate, cellulose derivatives; Cyclodextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
EP93104505A 1992-04-03 1993-03-19 Cytarabine ocfosfate hard capsule Expired - Lifetime EP0563697B1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
JP109053/92 1992-04-03
JP10905392 1992-04-03
JP10905392 1992-04-03

Publications (3)

Publication Number Publication Date
EP0563697A2 EP0563697A2 (en) 1993-10-06
EP0563697A3 true EP0563697A3 (en) 1994-06-01
EP0563697B1 EP0563697B1 (en) 2001-07-04

Family

ID=14500416

Family Applications (1)

Application Number Title Priority Date Filing Date
EP93104505A Expired - Lifetime EP0563697B1 (en) 1992-04-03 1993-03-19 Cytarabine ocfosfate hard capsule

Country Status (14)

Country Link
US (1) US5512298A (en)
EP (1) EP0563697B1 (en)
KR (1) KR100267525B1 (en)
CN (1) CN1039673C (en)
AU (1) AU657044B2 (en)
BR (1) BR9301373A (en)
CA (1) CA2093258C (en)
CZ (1) CZ282844B6 (en)
DE (1) DE69330392T2 (en)
ES (1) ES2160582T3 (en)
HU (1) HU217810B (en)
PL (1) PL171011B1 (en)
RU (1) RU2116069C1 (en)
TW (1) TW266160B (en)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP4982084B2 (en) * 2004-02-09 2012-07-25 株式会社サンギ Antitumor agent
US7576216B2 (en) * 2004-07-30 2009-08-18 Abbott Laboratories Preparation of pyridonecarboxylic acid antibacterials
US7524831B2 (en) 2005-03-02 2009-04-28 Schering Corporation Treatments for Flaviviridae virus infection
US8293274B2 (en) * 2005-04-06 2012-10-23 Kabushiki Kaisha Sangi Intestinal absorptive anti-tumor agent
DK1868581T3 (en) * 2005-04-11 2012-07-09 Abbott Lab Pharmaceutical compositions with improved dissolution profiles for poorly soluble drugs
RU2657833C2 (en) 2015-12-01 2018-06-15 Общество С Ограниченной Ответственностью "Остерос Биомедика" Stabilized dosage form of etidronate-cytarabine conjugate and its application
EA030671B1 (en) 2016-07-20 2018-09-28 Общество С Ограниченной Ответственностью "Остерос Биомедика" Preparation for treating bone lesions caused by malignant neoplasms

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3859431A (en) * 1973-01-04 1975-01-07 Lilly Industries Ltd Drug formulations
DE2924691A1 (en) * 1978-06-20 1980-01-17 Mineo Saneyoshi MEDICINAL PRODUCTS FOR NON-INJECTABLE ADMINISTRATION
US4681765A (en) * 1984-09-13 1987-07-21 American Home Products Corporation Rapid releasing triamterene containing gelatin capsule dosage forms for once daily antihypertensive use
EP0239015A2 (en) * 1986-03-24 1987-09-30 Nippon Kayaku Kabushiki Kaisha Process for producing 1-Beta-D-Arabinofuranosylcytosine-5'-stearylphosphate monosodium salt and monohydrate thereof, and pharmaceutical composition containing the latter
WO1987005804A1 (en) * 1986-04-01 1987-10-08 The Upjohn Company Methylprednisolone/sodium carboxymethyl starch tablet composition

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5223503A (en) * 1991-04-29 1993-06-29 Eli Lilly And Company 6-substituted pyrido[2,3-d]pyrimidines as antineoplastic agents

Patent Citations (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3859431A (en) * 1973-01-04 1975-01-07 Lilly Industries Ltd Drug formulations
DE2924691A1 (en) * 1978-06-20 1980-01-17 Mineo Saneyoshi MEDICINAL PRODUCTS FOR NON-INJECTABLE ADMINISTRATION
US4542021A (en) * 1978-06-20 1985-09-17 Yamasa Shoyu Kabushiki Kaisha Antitumor compositions for non-injection administration
US4681765A (en) * 1984-09-13 1987-07-21 American Home Products Corporation Rapid releasing triamterene containing gelatin capsule dosage forms for once daily antihypertensive use
EP0239015A2 (en) * 1986-03-24 1987-09-30 Nippon Kayaku Kabushiki Kaisha Process for producing 1-Beta-D-Arabinofuranosylcytosine-5'-stearylphosphate monosodium salt and monohydrate thereof, and pharmaceutical composition containing the latter
US4812560A (en) * 1986-03-24 1989-03-14 Yamasa Shoyu Kabushiki Kaisha Process for producing 1-β-D-arabinofuranosylcytosine-5'-stearylphosphate monosodium salt and monohydrate thereof
WO1987005804A1 (en) * 1986-04-01 1987-10-08 The Upjohn Company Methylprednisolone/sodium carboxymethyl starch tablet composition

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
CHEMICAL ABSTRACTS, vol. 103, no. 8, 26 August 1985, Columbus, Ohio, US; abstract no. 59243e, P. DE BEUKELAER ET AL: "The influence of the swelling characteristics of starch and starch derivatives on the disintegration of powders, packed in hard gelatin capsules" *
CHEMICAL ABSTRACTS, vol. 109, no. 12, 19 September 1988, Columbus, Ohio, US; abstract no. 98727j, JOHN E. BOTZOLAKIS ET AL: "Disintegrating agents in hard gelatin capsules. Part II: Swelling efficiency" *

Also Published As

Publication number Publication date
KR930021206A (en) 1993-11-22
AU3555893A (en) 1993-10-07
CA2093258C (en) 2003-01-14
BR9301373A (en) 1993-10-13
CN1039673C (en) 1998-09-09
EP0563697A2 (en) 1993-10-06
RU2116069C1 (en) 1998-07-27
CZ57793A3 (en) 1994-02-16
PL171011B1 (en) 1997-02-28
DE69330392D1 (en) 2001-08-09
HUT65314A (en) 1994-05-02
HU217810B (en) 2000-04-28
DE69330392T2 (en) 2001-11-08
PL298338A1 (en) 1993-12-13
ES2160582T3 (en) 2001-11-16
US5512298A (en) 1996-04-30
EP0563697B1 (en) 2001-07-04
CA2093258A1 (en) 1993-10-04
AU657044B2 (en) 1995-02-23
HU9300974D0 (en) 1993-06-28
CN1077888A (en) 1993-11-03
CZ282844B6 (en) 1997-10-15
TW266160B (en) 1995-12-21
KR100267525B1 (en) 2000-12-01

Similar Documents

Publication Publication Date Title
EP0479406A3 (en) Helmet
EG18661A (en) Protection of 2 , 3 - dideoxy - 2 - 3 didehy dronucheosides
GB8919556D0 (en) Periscope
EP0479407A3 (en) Helmet
EP0592130A3 (en) Hard capsules.
GB9223146D0 (en) Vented capsule
AU108030S (en) Capsule
GB8910031D0 (en) Shell
ZA937633B (en) Benzofuran derivatives
EP0563697A3 (en) Cytarabine ocfosfate hard capsule
GB9214782D0 (en) Helmet
GB8801564D0 (en) Protection
IL89599A0 (en) Armor
GB8806312D0 (en) Helmets
GB9113877D0 (en) Helmets
CA60942S (en) Capsule
GB9021068D0 (en) Capsules
GB9022698D0 (en) Security arrangement
GB8816921D0 (en) Camouflage
GB9026085D0 (en) Security transfers
CA71480S (en) Helmet
CA70426S (en) Helmet
CA66471S (en) Helmet
CA66479S (en) Headband
GB9216399D0 (en) Helmet

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

AK Designated contracting states

Kind code of ref document: A2

Designated state(s): DE ES FR GB IT NL SE

PUAL Search report despatched

Free format text: ORIGINAL CODE: 0009013

17P Request for examination filed

Effective date: 19940211

AK Designated contracting states

Kind code of ref document: A3

Designated state(s): DE ES FR GB IT NL SE

17Q First examination report despatched

Effective date: 19981203

GRAG Despatch of communication of intention to grant

Free format text: ORIGINAL CODE: EPIDOS AGRA

GRAG Despatch of communication of intention to grant

Free format text: ORIGINAL CODE: EPIDOS AGRA

GRAH Despatch of communication of intention to grant a patent

Free format text: ORIGINAL CODE: EPIDOS IGRA

GRAH Despatch of communication of intention to grant a patent

Free format text: ORIGINAL CODE: EPIDOS IGRA

GRAA (expected) grant

Free format text: ORIGINAL CODE: 0009210

ITF It: translation for a ep patent filed

Owner name: BARZANO' E ZANARDO ROMA S.P.A.

AK Designated contracting states

Kind code of ref document: B1

Designated state(s): DE ES FR GB IT NL SE

REF Corresponds to:

Ref document number: 69330392

Country of ref document: DE

Date of ref document: 20010809

ET Fr: translation filed
REG Reference to a national code

Ref country code: ES

Ref legal event code: FG2A

Ref document number: 2160582

Country of ref document: ES

Kind code of ref document: T3

REG Reference to a national code

Ref country code: GB

Ref legal event code: IF02

PLBE No opposition filed within time limit

Free format text: ORIGINAL CODE: 0009261

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: NO OPPOSITION FILED WITHIN TIME LIMIT

26N No opposition filed
PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: ES

Payment date: 20050222

Year of fee payment: 13

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: SE

Payment date: 20050304

Year of fee payment: 13

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: GB

Payment date: 20050316

Year of fee payment: 13

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: FR

Payment date: 20050317

Year of fee payment: 13

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: NL

Payment date: 20050331

Year of fee payment: 13

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: DE

Payment date: 20050520

Year of fee payment: 13

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: GB

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20060319

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: SE

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20060320

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: ES

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20060321

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: IT

Payment date: 20060331

Year of fee payment: 14

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: NL

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20061001

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: DE

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20061003

EUG Se: european patent has lapsed
GBPC Gb: european patent ceased through non-payment of renewal fee

Effective date: 20060319

NLV4 Nl: lapsed or anulled due to non-payment of the annual fee

Effective date: 20061001

REG Reference to a national code

Ref country code: FR

Ref legal event code: ST

Effective date: 20061130

REG Reference to a national code

Ref country code: ES

Ref legal event code: FD2A

Effective date: 20060321

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: FR

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20060331

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: IT

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20070319